LON:GSK

GSK (GSK) Share Forecast, Price & News

GBX 1,371

-21.20 (-1.52%)

(As of 05/30/2023 ET)

Compare

Today's Range: 1,365.80
▼
1,407
50-Day Range: 1,371
▼
1,523
52-Week Range: 1,280.92
▼
2,280.50

Volume: 4.45 million shs
Average Volume: 7.72 million shs
Market Capitalization: £55.53 billion

P/E Ratio: 1,257.80
Dividend Yield: 4.08%
Price Target: GBX 1,573.33

Profile Analyst Ratings Chart Competitors Dividend Insider Trades Headlines Options Chain Sustainability

GSK MarketRank™ Forecast

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 14.8% Upside
GBX 1,573.33 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.56
Upright™ Environmental Score
News Sentiment: 0.29
Based on 9 Articles This Week
Insider Trading: Acquiring Shares
£3.25 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
GSK has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 4 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 1,573.33, GSK has a forecasted upside of 14.8% from its current price of GBX 1,371.
Amount of Analyst Coverage
GSK has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for GSK.

1.7

Dividend Strength

Dividend Leadership
GSK is a leading dividend payer. It pays a dividend yield of 4.01%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
GSK does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of GSK is 5,137.61%. Payout ratios above 75% are not desirable because they may not be sustainable.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GSK has received a 66.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "HIV medication", "Shingles vaccines", "Mouthwash", "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Clinical research services for the respiratory system" products. See details.
Environmental Sustainability
The Environmental Impact score for GSK is -1.56.

1.8

News and Social Media Coverage

News Sentiment
GSK has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for GSK this week, compared to 6 articles on an average week.
Search Interest
Only 68 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GSK insiders have bought more of their company's stock than they have sold. Specifically, they have bought £32,495.86 in company stock and sold GBX 0 in company stock.
Percentage Held by Insiders
Only 1.75% of the stock of GSK is held by insiders.
Percentage Held by Institutions
43.27% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of GSK is 1,257.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 132.39.
Price to Earnings Ratio vs. Sector
The P/E ratio of GSK is 1,257.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 102.53.
Price to Earnings Growth Ratio
GSK has a PEG Ratio of 2.04. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
GSK has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GSK (LON:GSK) Stock

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Wave Life Sciences Ltd.; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

May 8, 2023 | marketbeat.com

ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results (GSK)

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

May 30, 2023 | finance.yahoo.com

Why GSK’s Emma Walmsley ‘violently rejects’ the idea of ‘superhero’ CEOs

May 30, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 30, 2023 | markets.businessinsider.com

EQS-News: CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

May 30, 2023 | americanbankingnews.com

Citigroup Reaffirms Neutral Rating for GSK (LON:GSK)

May 29, 2023 | uk.style.yahoo.com

4,950 abrdn shares and 716 GSK shares would give me £1,100 annual passive income

May 28, 2023 | americanbankingnews.com

GSK plc (LON:GSK) Receives GBX 1,595 Consensus PT from Brokerages

May 24, 2023 | msn.com

Unusual Put Option Trade in GSK Plc - ADR (GSK) Worth $226.93K

May 30, 2023 | Legacy Research (Affiliate) (Ad)

The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty

A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.

May 20, 2023 | americanbankingnews.com

GSK (LON:GSK) Earns "Buy" Rating from Deutsche Bank Aktiengesellschaft

May 19, 2023 | msn.com

Peering Into GSK's Recent Short Interest

May 19, 2023 | americanbankingnews.com

GSK (LON:GSK) Stock Rating Reaffirmed by Shore Capital

May 17, 2023 | sg.finance.yahoo.com

India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps

May 16, 2023 | benzinga.com

BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

May 16, 2023 | seekingalpha.com

Teva appeal against GSK over Coreg generics denied by Supreme Court

May 16, 2023 | americanbankingnews.com

GSK plc (GSK) To Go Ex-Dividend on May 18th

May 15, 2023 | msn.com

A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court

May 15, 2023 | fool.co.uk

I’d buy 886 GSK shares for £500 a year in passive income

May 15, 2023 | americanbankingnews.com

Insider Buying: GSK plc (LON:GSK) Insider Acquires £130.86 in Stock

May 13, 2023 | msn.com

I’d buy 665 GSK shares for £500 a year in passive income

May 13, 2023 | wsj.com

GSK Sells Haleon Shares at 335p Each, Raising GBP804M

May 13, 2023 | msn.com

GSK sells partial stake in spin-off firm Haleon at discount

May 13, 2023 | finance.yahoo.com

Interested In GSK's (LON:GSK) Upcoming UK£0.14 Dividend? You Have Four Days Left

May 12, 2023 | finance.yahoo.com

GSK's Meningitis Vaccine Candidate: Crushing Clinical Trials or Just Playing Catch-up with Bexsero and Menveo?

May 12, 2023 | reuters.com

UPDATE 1-GSK says Canada court dismissed Zantac litigation

May 12, 2023 | msn.com

GSK offloads £804m worth of shares in spun out healthcare arm Haleon

May 11, 2023 | finance.yahoo.com

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Last Earnings: 7/29/2020
Ex-Dividend for 4/13 Dividend: 2/23/2023
Dividend Payable: 4/13/2023
Ex-Dividend for 7/13 Dividend: 5/18/2023
Today: 5/30/2023
Dividend Payable: 7/13/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:GSK
CUSIP: N/A
CIK: N/A
Web: www.gsk.com
Phone: +44-20-80475000
Fax: N/A
Employees: 90,096
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 1,573.33
High Stock Price Forecast: GBX 2,000
Low Stock Price Forecast: GBX 1,245
Forecasted Upside/Downside: +12.4%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 1.09
Trailing P/E Ratio: 1,284.70
Forward P/E Ratio: 10.22
P/E Growth: 2.04
Net Income: £4.46 billion
Net Margins: 50.35%
Pretax Margin: N/A
Return on Equity: 28.17%
Return on Assets: 6.36%

Debt

Debt-to-Equity Ratio: 184.80
Current Ratio: 0.95
Quick Ratio: 0.73

Sales & Book Value

Annual Sales: £29.08 billion
Price / Sales: 1.95
Cash Flow: GBX 171.92 per share
Price / Cash Flow: 8.15
Book Value: GBX 292 per share
Price / Book: 4.80

Miscellaneous

Outstanding Shares: 4,050,000,000
Free Float: N/A
Market Cap: £56.71 billion
Optionable: Optionable
Beta: 0.28

Key Executives

Ms. Emma Natasha Walmsley (Age 53)
CEO & Director
Comp: $3.88M

Mr. Iain James Mackay (Age 61)
CFO & Exec. Director
Comp: $2.88M

Ms. Julie Brown (Age 61)
Chief Financial Officer

Ms. Shobie Ramakrishnan
Chief Digital & Technology Officer

Mr. Tony Wood
Chief Scientific Officer

Ms. Sarah Elton-Farr
Head of Investor Relations

Mr. James Ford
Sr. VP & Group Gen. Counsel of Legal & Compliance

Ms. Sally Jackson
Sr. VP of Global Communications & CEO Office

Ms. Diana Conrad
Chief People Officer

Mr. David Simon Redfern (Age 57)
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.
What is GSK's stock price forecast for 2023?: 8 equities research analysts have issued 12-month price targets for GSK's stock. Their GSK share price forecasts range from GBX 1,245 to GBX 2,000. On average, they expect the company's stock price to reach GBX 1,573.33 in the next year. This suggests a possible upside of 12.4% from the stock's current price.
View analysts price targets for GSK or view top-rated stocks among Wall Street analysts.
How have GSK shares performed in 2023?: GSK's stock was trading at GBX 1,437.60 at the start of the year. Since then, GSK shares have decreased by 2.6% and is now trading at GBX 1,400.33.
View the best growth stocks for 2023 here.
How were GSK's earnings last quarter?: GSK plc (LON:GSK) released its earnings results on Wednesday, July, 29th. The company reported $56.90 earnings per share (EPS) for the quarter. GSK had a trailing twelve-month return on equity of 28.17% and a net margin of 50.35%.
How often does GSK pay dividends? What is the dividend yield for GSK?: GSK declared a dividend on Wednesday, April 26th. Shareholders of record on Thursday, May 18th will be paid a dividend of GBX 14 per share on Thursday, July 13th. This represents a yield of 0.93%. The ex-dividend date is Thursday, May 18th. This is a positive change from the stock's previous dividend of GBX 13.75. The official announcement can be seen at this link.
Read our dividend analysis for GSK.
Is GSK a good dividend stock?: GSK (LON:GSK) pays an annual dividend of GBX 56 per share and currently has a dividend yield of 4.01%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 5,137.61%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).
What is GSK's stock symbol?: GSK trades on the London Stock Exchange (LON) under the ticker symbol "GSK."
How do I buy shares of GSK?: Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is GSK's stock price today?: One share of GSK stock can currently be purchased for approximately GBX 1,400.33.
How much money does GSK make?: GSK (LON:GSK) has a market capitalization of £56.71 billion and generates £29.08 billion in revenue each year. The company earns £4.46 billion in net income (profit) each year or GBX 1.09 on an earnings per share basis.
How many employees does GSK have?: The company employs 90,096 workers across the globe.
How can I contact GSK?: GSK's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The official website for the company is www.gsk.com. The company can be reached via phone at +44-20-80475000.

This page (LON:GSK) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GSK (GSK) Share Forecast, Price & News

GSK MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GSK (LON:GSK) Stock

GSK Stock News Headlines

GSK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

GSK Stock - Frequently Asked Questions

Overall MarketRank^™